Sevilay Altıntaş

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung et al. · The Lancet · 2022 · 580 citations · Full text

Breast Oncology, Medicine, Clinical Trials +8

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia

Laurent Bastit, A. Vandebroek, Sevilay Altıntaş et al. · Journal of Clinical Oncology · 2008 · 194 citations · Full text

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago et al. · The Lancet Oncology · 2018 · 126 citations

Breast Oncology, Oncology, Metronomic Therapy +7

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Christian Marth, Ignace Vergote, Giovanni Scambia et al. · European Journal of Cancer · 2016 · 79 citations

Resistant Ovarian Cancer, Medicine, Gynecology +7

In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment

Peter A. van Dam, Pieter‐Jan van Dam, Christian Rolfo et al. · Oncotarget · 2015 · 58 citations · Full text

Cervical Cancer Biomarkers, Cervical Cancer, Silico Pathway Analysis +12